Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-02: CD19-CAR T Cell Immunotherapy for CD19+ Leukemia
NCT02028455Phase 2Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Feb 2014
- Primary completion
- Aug 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19R(EQ)28zeta/EGFRt+ T cells in acute leukemia, non-Hodgkin lymphoma (NHL), sponsored by Seattle Children's. Started Feb 2014; status: active, not recruiting.
02
Drugs
CD19R(EQ)28zeta/EGFRt+ T cells
03
Conditions
acute leukemianon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02028455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02028455.